Singapore, Aug. 11 -- Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, has announced an exclusive collaboration with New Zealand-basedPacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong.

Under this partnership, Codex Genetics will offer access to Cxbladder's full range of clinically validated tests-including Cxbladder Detect, Cxbladder Monitor, and Cxbladder Triage-designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to ...